Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 2/20 | 0.64 |
| ▸ | TYMP | P19971 | 4/20 | 0.53 |
| ▸ | PYGM | P11217 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALB | P02768 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414718 | 1.00 | TK2 (0.64) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL12718467 | 0.93 | TK2 (0.65) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL12748371 | 0.93 | TK2 (0.65) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL12718222 | 0.93 | TK2 (0.65) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL12749200 | 0.93 | TK2 (0.65) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL24229243 | 0.91 | TK2 (0.67) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL5502489 | 0.91 | TK2 (0.67) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL5502493 | 0.91 | TK2 (0.67) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL10267691 | 0.91 | TK2 (0.67) | TK2TYMPPYGMALDH1A1LMNA | |
| SCHEMBL12718535 | 0.90 | TK2 (0.69) | TK2TYMPPYGMALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050266422-A1 | Fluoroalkoxy, nucleosides, nucleotides, and polynucleotides | SIRNA THERAPEUTICS, INC. (US) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050266422-A1 | Fluoroalkoxy, nucleosides, nucleotides, and polynucleotides | NSUN3, IRF3, SNRPF | TK2 944/4885TYMP 598/4885PYGM 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.